Oppenheimer & Co. Inc. Grows Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Oppenheimer & Co. Inc. increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 4.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 40,091 shares of the company’s stock after acquiring an additional 1,636 shares during the period. Oppenheimer & Co. Inc.’s holdings in Dyne Therapeutics were worth $1,440,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its holdings in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares during the last quarter. US Bancorp DE grew its position in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the last quarter. Values First Advisors Inc. acquired a new position in Dyne Therapeutics during the 3rd quarter valued at approximately $62,000. Amalgamated Bank raised its stake in Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after acquiring an additional 796 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Dyne Therapeutics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after acquiring an additional 709 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insider Activity

In other Dyne Therapeutics news, CEO John Cox acquired 32,000 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the transaction, the chief executive officer now owns 8,000 shares of the company’s stock, valued at approximately $264,320. The trade was a -133.33 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the sale, the senior vice president now owns 98,568 shares in the company, valued at $3,405,524.40. This represents a 1.39 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is currently owned by insiders.

Dyne Therapeutics Stock Down 6.3 %

Shares of NASDAQ DYN opened at $28.39 on Monday. The firm has a 50-day simple moving average of $32.48 and a 200-day simple moving average of $35.24. Dyne Therapeutics, Inc. has a 52 week low of $9.76 and a 52 week high of $47.45. The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of -7.97 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.39 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on DYN. Morgan Stanley increased their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. Chardan Capital reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Finally, Piper Sandler reissued an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.